Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape

Raphael Ferreira^{1,2} · Florian David^{1,2} · Jens Nielsen^{1,2,3}

Received: 7 November 2017 / Accepted: 19 December 2017 / Published online: 24 January 2018
© The Author(s) 2018. This article is an open access publication

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) is poised to become one of the key scientific discoveries of the twenty-first century. Originating from *prokaryotic* and *archaeal* immune systems to counter phage invasions, CRISPR-based applications have been tailored for manipulating a broad range of living organisms. From the different elucidated types of CRISPR mechanisms, the type II system adapted from *Streptococcus pyogenes* has been the most exploited as a tool for genome engineering and gene regulation. In this review, we describe the different applications of CRISPR/Cas9 technology in the industrial biotechnology field. Next, we detail the current status of the patent landscape, highlighting its exploitation through different companies, and conclude with future perspectives of this technology.

Introduction

Throughout the years following the discovery of the structure of DNA, scientists have endeavored to genetically manipulate organisms. Until recently, most of the genetic engineering tools developed were based on DNA:protein recognition principles, such as restriction enzymes, site-directed zinc finger nucleases (ZFs), and TAL effector nucleases (TALENs) [6, 47]. However, these tools are commonly experienced with difficulties in design, synthesis, and efficiency which altogether prevented a global widespread adoption, e.g. TALENs require 30–35 amino acids repeats, each only recognizing a single nucleotide (nt) [29]. On the other hand, the RNA-programmable CRISPR/Cas9 technology has led to a scientific revolution by solving all of the above-mentioned issues [20]. The technology relies on two elements: a protein, the CRISPR associated protein

(Cas9), and a RNA molecule, the guide RNA (gRNA) [5, 46]. Cas9, the first Cas protein used in genome editing, is a large multi-domain enzyme interacting with the gRNA, the target DNA, and the Protospacer Adjacent Motif sequence (PAM) (Fig. 1a). The gRNA element is composed of two distinct elements: the spacer, a 20 nt domain that binds to the DNA; and the scaffold, a ~ 79 nt domain that interacts with Cas9 (Fig. 1a). Once guided to the target, Cas9 catalytically cleaves the DNA sequence 3 nt upstream the 5'-NGG PAM, resulting in the activation of endogenous repair mechanisms, such as homologous recombination (HR) or non-homologous end joining (NHEJ) [2, 71] (Fig. 1b).

Expanding Cas9 features through enzyme engineering

The structural characterization of Cas9 has led to the development of mutagenized variants with various catalytic properties, specificities through different PAM recognition preferences and reduction in off-targeting [37, 55, 56, 90]. For example, Hirano et al. first characterized FnCas9 from *Francisella novicida* and, based on the characterized protein structure, created a variant recognizing a 5'-YG' PAM instead of the original 5'-NGG [37]. A 5'-YG PAM increases the target space availability for genome editing, i.e. any target followed by CG or TG is prone to be targeted by the gRNA:FnCas9 complex. Additionally, other CRISPR nucleases with different PAM preferences can also be used to increase the target space availability, e.g. FnCpf1

✉ Jens Nielsen
nielsenj@chalmers.se

¹ Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Göteborg, Sweden

² Novo Nordisk Foundation Center for Biosustainability, Chalmers University of Technology, 412 96 Göteborg, Sweden

³ Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark

Fig. 1 CRISPR/Cas9 for genome editing and gene regulation. **a** The gRNA:Cas9 complex binding to the DNA target. In green, the spacer region which interacts with the DNA target. **b** DNA cut generated from the Cas9 nuclease activity. **c** Gene regulation with dCas9 physically blocking the RNA polymerase from binding to the promoter

region. **d** CRISPR interference further enhanced with dCas9 fused with transcriptional regulators. **e** gRNA scaffold extended with stem-loops recruiting regulator elements. **f** Multiplexing gRNAs from a single transcript through endoribonuclease or self-processing elements

a type V CRISPR system from *F. novicida* which recognizes a T-rich PAM 5'-TTTN [26, 101] (Fig. 1b). In another approach, mutation in one of the nuclease activity domains (RuvC^{D10A} or HNH^{H840A}, Cas9n) was shown to result in a modified Cas9 only capable of performing single-strand DNA breaks (nick) instead of the original blunt DNA break [80]. This feature has been shown to reduce off-targeting and enhance HR in some organisms [12, 70]. By extension, 'paired nickases', i.e. using two adjacent gRNAs with Cas9n, can efficiently introduce both indel mutations and HR events with a single-stranded DNA oligo-nucleotide donor template in mammalian cells [28, 10, 80]. Complete disruption of the endonuclease activities (RuvC^{D10A} along with HNH^{H840A}) results in a catalytically inactive Cas9, or dead-Cas9 (dCas9) [78, 79]. This has been exploited to physically block the transcriptional machinery when targeted in the promoter region of a gene of interest, coined CRISPR interference (CRISPRi) [22, 34] (Fig. 1c). Additionally, repression can be further enhanced by fusing dCas9 with repressive domains, such as the mammalian transcriptional repressor domain Mxi1 [33] (Fig. 1d). Gander et al. have recently exploited dCas9-Mxi1 repressive mechanism to effectively built up to seven layers of synthetic NOR gate circuits, in *S. cerevisiae*

[30] (Figs. 1d, 2b). Likewise, dCas9 can be coupled to activating transcription factor domains, such as the tripartite VP64-p65-Rta (VPR) or the RNAP ω -subunit (*rpoZ*), which have been characterized as powerful tools for activating genes [4, 7, 44, 91] (Fig. 1d). Similarly, epigenetic regulators, such as methylation, demethylation, acetylation and deacetylation domains, can be fused to dCas9 to influence chromatin structure and, therefore, interfere with the transcriptional signature of a promoter [36, 50, 54]. Hilton et al. reported the fusion of dCas9 with the histone acetyltransferase domain of the human E1A-associated protein p300 (dCas9-p300), which significantly modulated the chromatin structure, and resulted in a 4000-fold up regulation with a single gRNA [36].

The gRNA characteristics and extensions

Cas9 can be guided virtually anywhere in the genome where a PAM sequence is present. However, several parameters, such as nucleotide motifs, particularity of the PAM sequence, and mismatches in the guide, have to be taken into account for a correct cleavage in the target DNA [91]. Recently, efforts have been made to solve

Fig. 2 Example of application in drug discovery and synthetic biology. **a** Genome-wide pooled gRNA libraries targeting all pairs of 73 cancer genes with dual guide RNAs in three mammalian cell lines.

b Example of logic circuits made with dCas9-Mxi1 NOR gates with GFP signal used as output similar to Gander et al. study

target efficiency through algorithms predicting the ability of the gRNA to facilitate DNA cleavage by Cas9 at the intended target site by employing refined machine learning methods and incorporating large training datasets [18, 19]. The sequence accuracy of the gRNA is also essential to achieve a correct base-pairing between the gRNA and the target DNA. Most commonly, RNA pol. III promoters are used to transcribe gRNAs. These are scarce and more importantly, some of them contain idiosyncratic features, e.g. U6 mammalian promoter requires to have a G at the 5' end of the transcript [28]. Transcriptional expression can be improved by inserting self-processing elements, such as HDV ribozyme and tRNAs, at the 5' or 3' end to prevent potential degradation of the transcript [49, 83]. Processing elements can also be exploited to multiplex several gRNAs in a row by collocating those element between each gRNAs [17] (Fig. 1e). Several examples, such as the type III CRISPR-Csy4 [25, 76] or natural CRISPR array [1, 14] have been shown to efficiently generate multiple

gRNAs from a single transcript (Fig. 1e). Notably, while Cpf1 belongs to the same CRISPR class II as Cas9, i.e. only a single crRNA-effector enzyme and no tracrRNA part is required for cutting DNA. It differs from it by possessing a specific RNA processing domain that allows to process the crRNA into multiple gRNAs [55, 69, 92, 101].

Finally, the gRNA scaffold can be extended to include effector protein recruitment stem-loops, which has been shown to enhance transcriptional regulation [8, 44, 100] (Fig. 1d). With that strategy, Zalatan et al. were able to design gRNAs to either recruit activator or repressor elements, which ultimately established both, repression and activation of specific gene targets at the same time [100] (Fig. 1d). This platform offers a considerable advantage in comparison to dCas9 fused to a regulator, as it is not limited to which transcriptional regulator is fused to dCas9, but to which stem-loop is connected to the gRNA scaffold.

Another high potential application area for the CRISPR technology is systematic genetic screening

Table 1 Non-exhaustive list of studies applying CRISPR and CRISPRi for metabolic engineering purposes

Type	Organism	Compound targeted	Fold or/and titer	Comments	References
CRISPR	<i>Aspergillus niger</i>	Galactaric acid	~4.3 g L ⁻¹	Proof-of-concept: Genome engineering for the production of galactaric acid from galacturonic acid	[58]
Both	<i>Bacillus subtilis</i>	hyaluronic acid (HA) and galactosidase	8-fold repression for galactosidase/717 mg L ⁻¹ using sucrose as carbon source for HA	Proof-of-concept: CRISPR and CRISPRi toolkits	[97]
Both	<i>Clostridium cellulovorans</i> , <i>C. beijerinckii</i>	Solvents	3.2-fold/22.1 g L ⁻¹	CRISPR and CRISPRi strategy for the production of various solvents	[96]
CRISPRi	<i>Corynebacterium glutamicum</i>	Lysine and glutamate	Lysine: ~2.5-fold/2.7 g L ⁻¹	Repression strategy to enhance production of aminoacids	[11]
CRISPRi	<i>Corynebacterium glutamicum</i>	Shikimate	115% titer increase/7.76 g L ⁻¹	Repression strategy for shikimate production	[102]
CRISPR	<i>Corynebacterium glutamicum</i>	γ -aminobutyric acid	~27.5 g L ⁻¹	Method: CRISPR/Cas9-coupled recombination mediated with the recombinase RecT	[10]
CRISPR	<i>Escherichia coli</i>	Xylose pathway	3-fold increase of xylose-utilization rate/0.80 g 1gDCW ⁻¹ h ⁻¹	Method: Integration of RBS libraries facilitated with CRISPR/Cas9	[103]
CRISPRi	<i>Escherichia coli</i>	Isoprenoids	71 mg L ⁻¹ Lycopene	Fine-tuning of the expression of all the MVA pathway genes in the context of operon and blocked the transcription of the acetoacetyl-CoA thiolase enzyme that catalyzes the first step in the MVA pathway. Coupling CRISPRi to cell growth by regulating an endogenous essential gene (<i>ispA</i>) increased isoprene (C5) production	[53]
CRISPRi	<i>Escherichia coli</i>	Naringenin	2.5-fold/~ 20 mg L ⁻¹	Multiplexed repression with proof-of-concept in naringenin production	[14]
CRISPRi	<i>Escherichia coli</i>	P(3HB-co-4HB)	~18 mol % of 4HB	Multiplexed gene repression of five genes involved in P(3HB-co-4HB) production pathway	[68]
CRISPR	<i>Escherichia coli</i>	Isopropanol	~0.75 mol mol ⁻¹	RBS libraries integration for 5 genes involved in isopropanol production	[64]
CRISPRi	<i>Escherichia coli</i>	Naringenin	7.4-fold/421.6 mg L ⁻¹	Repression of genes involved in cell proliferation in order to switch towards a production phase	[99]
CRISPRi	<i>Escherichia coli</i>	3-O-glucoside (P3G)	21-fold/56.3 mg L ⁻¹	CRISPRi of a transcription factor regulating several enzyme involved in P3G production pathway	[13]
CRISPR	<i>Escherichia coli</i>	β -carotene	3-fold/2.0 g L ⁻¹	Iterative genome editing for enhanced production of β -carotene	[63]

Table 1 (continued)

Type	Organism	Compound targeted	Fold or/and titer	Comments	References
Both	<i>Escherichia coli</i>	1,4-BDO	85%/1.8 g L ⁻¹	Two phases study: (1) several genome editings, followed by (2) CRISPRi mediated of endogenous genes diverting carbon fluxes from BDO production	[99]
CRISPR	<i>Myceliophthora</i> species	Cellulolytic enzyme activities	13.3-fold/2.2 U mL ⁻¹	Proof-of-concept: CRISPR in thermophilic fungi	[67]
CRISPR	<i>Saccharomyces boulardii</i>	Human lysozyme secretion	~450 U mL ⁻¹	Proof-of-concept in <i>Saccharomyces boulardii</i>	[66]
CRISPRi	<i>Saccharomyces cerevisiae</i>	Violacein	16-fold/–	Proof-of-concept: Extended RNA scaffold for simultaneous upregulation and downregulation of 5 genes involved in violacein pathway	[100]
CRISPRi	<i>Saccharomyces cerevisiae</i>	Glycerol and 3-dehydroshikimate	7.8-fold increase in 3-dehydroshikimate/126 g L ⁻¹	Systematically test enzyme perturbation sensitivities (STEPS) platform	[17]
CRISPRi	<i>Saccharomyces cerevisiae</i>	β-carotene; Triacylglycerols	Up to 2-fold/15 mg gCDW ⁻¹ TAG	Fine-tuning of 2 biosynthetic pathways: TAG and B-carotene	[44]
Both	<i>Saccharomyces cerevisiae</i>	Naringenin	2-fold/~ 8 mg L ⁻¹ OD600 ⁻¹	Cas9/dCas9 combinatorial strategy for genetic engineering and transcriptional control of Naringenin pathway	[94]
CRISPR	<i>Saccharomyces cerevisiae</i>	Mevalonate	41-fold/10.38 μM	5 marker-free genome edits in a single transformation	[41]
CRISPR	<i>Saccharomyces cerevisiae</i>	Cellobiose fermentation	10-fold/–	Method: better quality gRNA by adding a 5' hepatitis delta virus (HDV) ribozyme. Integration of a DNA library (cdt-1 gene)	[83]
CRISPR	<i>Saccharomyces cerevisiae</i> , <i>Kluyveromyces fragilis</i>	Muconic acid	~2.7 g L ⁻¹	Six DNA fragments (24 kb) in a single transformation	[38]
CRISPR	<i>Schizosaccharomyces pombe</i>	Lactic acid	~25.2 g L ⁻¹	Proof-of-concept: CRISPR for integration of lactic acid producing genes in <i>S. pombe</i>	[77]
CRISPR	<i>Solanum lycopersicum</i>	γ-aminobutyric acid (GABA)	19-fold/~ 60 μmol gFW ⁻¹	Multiplexed genome editing (up to 4 edited genes) in tomato plant for enhanced production of GABA	[61]
CRISPR	<i>Streptomyces pristinaespiralis</i>	Pristinamycin I	2.4-fold/132 mg L ⁻¹	120 kb Biosynthetic gene cluster integrated via CRISPR	[72]
CRISPRi	<i>Synechococcus</i> sp. strain PCC 7002	Lactate	2-fold increase/0.092 mM	Proof of Concept: reversible and tunable repression of heterologous and native genes	[35]
CRISPR	<i>Synechococcus elongatus</i> PCC 7942	Succinate	11-fold/435 μg L ⁻¹	Proof-of-concept: CRISPR for genome engineering in cyanobacteria	[60]

Table 1 (continued)

Type	Organism	Compound targeted	Fold or/and titer	Comments	References
CRISPRi	<i>Synechococcus elongatus</i> PCC 7942	Succinate	12.5-fold/0.63 mg L ⁻¹	CRISPRi to efficiently downregulate genes diverting fluxes from succinate production	[40]
CRISPRi	<i>Synechococcus</i> sp. strain PCC 6803	Fatty alcohol	3-fold/10.3 mg gCDW ⁻¹	Simultaneous downregulation of 6 genes for fatty alcohol production	[48]

employing gRNA libraries. Due to the short length of gRNAs (~ 100nt), accurate predictability, and easy cloning approaches, genome-wide gRNA libraries have been successfully designed to knockout and regulate genes throughout the entire genome [31]. For example, Shen et al. developed a systematic approach to map synthetic lethality genes by targeting all pairs of 73 cancer genes with dual guide RNAs in three different cancer cell lines (Fig. 2a). Their strategy involved nine gRNA pairs per combination, the library comprised 23,652 double-gene-knockout constructs with two replicates in three cell lines which ultimately led to a total of 141,912 interactions and to the discovery of 120 potential drugs candidates [86] (Fig. 2a).

Industrial applications through metabolic engineering

Genome engineering

There has been an increasing interest in improving microbial cell factories through metabolic engineering approaches using CRISPR/Cas9 technology [42]. The efficiency and versatility offered by CRISPR tools have shown great potential in rewiring the metabolic network of host cells to enhance their production of metabolites used in various areas of industrial biotech ranging from applications as biofuels to chemical building blocks and pharmaceuticals (Table 1). Metabolic pathway optimization towards the product of interest commonly requires deletions of multiple genes, e.g. competitive metabolic pathways, which is traditionally performed through iterative cycles of genetic marker integration and removal [15]. Conversely, the CRISPR technology does not necessitate integrative markers, and several efficient marker-free approaches were developed to perform multiplexed genome editing, e.g. knockouts, point-mutations [41, 93] and gene integration [45], which extensively reduced the time and effort required to perform targeted strain engineering. The CRISPR technology has also improved genetic engineering in difficult-to-engineer industrial organisms, such as food crops. Among several examples (Table 1), Li et al. reported a significant site-specific gene replacement of the 5-enolpyruvylshikimate-3-phosphate synthase (*EPSPS*) in rice plants using a pair of gRNAs targeting introns, ultimately converting the crop into a glyphosate-resistant one (Fig. 3c) [62]. More recently, several studies have highlighted significant improvements in genome editing in plants using DNA-free CRISPR/Cas9 ribonucleoproteins [65, 98].

Besides its multiplexing qualities, CRISPR has also shown great efficiency to integrate large pathways and

libraries [38, 88]. For example, Shi et al. specifically designed gRNAs to target multiple delta sites in the yeast genome, ultimately achieving 18-copy genomic integrations of a 24 kb combined xylose utilization and (R,R)-2,3-butanediol (BDO) production pathway in a single step, in *S. cerevisiae* [88]. DNA libraries, such as error-prone PCRs derived or double-stranded fragments obtained from DNA synthesizing companies, can be genomically integrated to find variants of a studied enzyme with enhanced catalytic activities or optimal level of expression [64, 83]. Genomically integrated DNA libraries offer several advantages compared to plasmid based strategies, especially in terms of expression stability [83]. Liang et al. used that strategy to integrate 640 ribosome binding sites (RBS) for five different enzymes involved in the production of isopropanol in *E. coli* [64] (Fig. 3a). After multiple rounds of screening for strains carrying the best RBS variants, i.e. optimal expression of the gene leading to a higher isopropanol titer, a final strain producing 7.1 g L⁻¹ of isopropanol was obtained [64].

dCas9—transcriptional regulation

Fine-tuning of biosynthetic pathways is a key step in the correct and efficient synthesis of a particular target compound (Nielsen and Keasling 2016). Traditional strategies have been relying on a limited number of characterized promoters to control gene expression, i.e. strong, weak, and inducible promoters [51]. As mentioned above, besides its efficient endonuclease activity, CRISPR can enable gene expression modulation through the deactivated form of the Cas9 protein, dCas9 [59, 79]. Once bound to, or in the vicinity of the transcriptional start site (TSS), the gRNA:dCas9 complex can significantly alter the transcriptional expression by physically interfering with RNA polymerase binding [14, 43, 79]. Wu et al. recently exploited this strategy in *E. coli* where they did a selective knockdown of gene expression of enzymes that could divert the carbon flux away from the production of 1,4-Butanediol (BDO) [99]. They divided their study into two phases, (1) a heavy strain engineering approach through multiple genome edits such as gene knockouts, knockins, and point-mutations, and (2) optimization through fine tuning of gene expression of three genes competing with the production of BDO. This strategy increased the 1,4-BDO titer by 100% from phase (1) to phase (2), resulting in a final titer of 1.8 g L⁻¹ 1,4-BDO (Table 1).

In addition, graded transcriptional patterns can be achieved depending on where the dCas9 complex binds in the promoter region, e.g. on the TSS for strong downregulation or more distanced from it for a medium repression. Thus, optimal gene expression can be elucidated by targeting dCas9 at different positions on the studied promoter [16, 17, 44]. This feature is subject to several parameters,

such as the distance to TSS, condition dependent presence of transcription factors, chromatin accessibility, but the complete understanding of how to obtain precise regulation has yet to be characterized and is most likely dependent on specific promoters [57, 91]. For example, Deaner et al. recently developed a graded expression platform that can be employed to systematically test enzyme perturbation sensitivities (STEPS), and assists to identify potential flux limiting enzymes arising from production pathways [16] (Fig. 3d; Table 1). Their strategy relied on targeting dCas9, with either a repressor and activator domain, at different positions of several promoters of genes, and analyze their effect on the final titer. For example, while optimizing glycerol production, from the seven tested genes, one gRNA targeting *GPD1* with dCas9-VPR led to a significant titer increase, highlighting its importance in the overall production pathway. Then they iteratively used STEPS to find a second bottleneck in *GPPI*, which ultimately led to a final titer ~ 28 g L⁻¹, a sevenfold increase compared with their original strain.

Patenting landscape

The patent landscape related to CRISPR/Cas9 technology is complex, constantly changing, with several main actors dominating the field [21]. Those include one hospital, five universities, and one researcher, namely: Massachusetts General Hospital, Duke University, the Broad Institute (joint Harvard and MIT entity), the University of California Berkeley, the University of Vienna and Emmanuelle Charpentier. These entities have granted broad exclusive licenses to “surrogate” companies such as Caribou Bioscience (Berkeley, Vienna University, Jennifer Doudna), CRISPR Therapeutics (E. Charpentier; therapeutic field) and ERS genomics (E. Charpentier; all applications, except human therapeutics). Additionally, several spin-out companies have been formed, e.g. Editas Medicine (Broad institute, Duke University, Massachusetts General Hospital; area of human therapeutics) and Intellia Therapeutics (Caribou Biosciences; human therapeutics) with focus on their own R&D activities in human therapy, and specific out-licensing in certain areas. Notably, Editas Medicine, CRISPR Therapeutics and Intellia Therapeutics are publicly registered in the NASDAQ Stock Market.

Regarding the different commercialization areas of these patents, three main application fields have formed: (1) CRISPR/Cas9 used in medical applications with focus on human therapeutics and drug discovery, (2) research tool applications, cell line and animal models, and (3) agriculture and food applications (Fig. 4).

Fig. 3 CRISPR applications in metabolic engineering. **a** CRISPR enabled trackable genome engineering (CREATE) strategy for optimal expression of 4 genes involved in isopropanol biosynthetic pathway. Integration of DNA libraries composed of variant RBS sequences. **b** Multiple integration of the xylose and BDO pathway into retroposons sites in *S. cerevisiae*. Retrotransposons are composed of similar DNA sequences, which ultimately allows to generate a promiscuous gRNA able to target several of these targets at once. **c** Genetic engineering in rice using dual gRNAs targeting *ESPS* introns for double amino acid substitution [T102I + P106S (TIPS)]. **d** Systematic testing of enzyme perturbation sensitivities (STEPS) approach to iteratively find bottleneck

In the area of human therapeutics, spin-outs originated from academic institutions and initial inventors are dominating the field with focus on R&D, licensing, and commercial partnering. We see specific exclusive licenses to newly formed companies in the field, e.g. for Chimeric Antigen Receptor T-cell therapy (CAR-T) (Juno, Novartis and Cellectis) or treatment of blood, eye and heart diseases (Casebia, and Editas Medicine), as well as broader licenses in using CRISPR as a drug for human therapeutics (AstraZeneca, Amri, Oxford Genetics and Evotec) (Figs. 4, 5).

In the area of research tools, non-exclusive licenses, mostly coming from the Broad Institute and Caribou Biosciences, are most prominent in the field. The applications range from licenses for general research tools, e.g. Clontech, Horizon, ATCC, GE-Healthcare, to specific licenses in the field of drug discovery, e.g. Evotec, Novartis, Regeneron, and applications in animal models, e.g. Taconic, Sage Labs, The Jackson Laboratory, and Knudra (Fig. 4).

In the area of agricultural and food applications, larger industry players, such as DowDupont, control the field with regards to patent holding and licensing. Their strategy included (1) the acquisition of Danisco in 2011, an agricultural/food ingredient company that made crucial progress in understanding CRISPR mechanism and the role of Cas9 [2], (2) agreements with Virginijus Siksnys from University of Vilnius, one of the founders of CRISPR technology [32, 84], and (3) exclusive cross-licenses from Caribou Bioscience and ERS Genomics specific for the agricultural field. In addition, Monsanto/Bayer Crop Science recently acquired a non-exclusive license from the Broad Institute for sole use in the agricultural sector. Another key player in the field of crop engineering is Calyxt, which acquired exclusive worldwide rights for CRISPR/Cas9 utilization in plants from the University of Minnesota, highlighting the complexity emerging from these patents and the different licensing structures in the field.

In the area of industrial biotechnology, CRISPR licenses are so far only obtained in a small number of cases, such as Evolva which acquired a license from ERS genomics for yeast and fungal engineering for biotechnological production of chemicals.

Because of the ongoing patent dispute between the Broad Institute and UC Berkeley/Charpentier, the licensing situation remains opaque. Currently, some of the Broad patents were granted in the beginning of 2017 while the UC Berkeley/E. Charpentier patents are still pending. A request of interference filed by UC Berkeley was turned down in the first round but has now gone to a second round with an appeal to the original decision. The hubbub created by the “battle” has incentivized several companies, e.g. Horizon, DowDupont, Sage labs, to acquire licenses from different main patent owners, to secure even exclusive access to the technology in a certain field.

A main area in CRISPR-based drug development is its use in cancer immunotherapy to reprogram enhanced CAR-T receptors for selectively targeting cancer cells [81]. The genetic modifications are done in vitro, making this approach a potential low hanging fruit for successful approval of CRISPR based medical therapies. A major milestone was recently achieved with two CAR-T based treatments approved by the FDA [73, 74]. Large companies and several startups acquired exclusive licensing from different CRISPR IP holders in the field, e.g. Novartis with Intellia Therapeutics, and Juno with Editas Medicine (Fig. 4).

Looking at all the different patents and patent applications in the field, the total number of patents encompasses over 90 granted patents and 1300 filed patents ranging from CRISPR/Cas9 components to delivery systems and applications [21]. Some of the main actors started to create patent pools to simplify the licensing process for commercial users. As such, agreements were made between CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics to maintain and coordinate prosecution of particular patent families. As direct competitors, a similar alliance has been formed between the Broad Institute, Rockefeller University, Harvard University, and MIT, through the intermediary of MPEG LA, LLC firm Sheridan [87].

Another strategy followed by certain entities in the field is to diversify their IP portfolio with the result of having priority for follow-on refinements of the previous patent applications. For example, Zhang and colleagues from the Broad Institute have discovered and filed patent protection for Cpf1, a robust alternative to Cas9 [21, 101].

Conclusion and discussion

Only recently discovered, CRISPR/Cas9 technology has already been enhanced to the point of fulfilling most of the genome editing and gene regulation currently demanded, ranging from the ability to perform multiple gene insertions, gene knockouts, combinatorial libraries, to advanced fine-tuning of biosynthetic pathways [23, 39, 47, 95]. However, off-targeting remains an important limitation to the

Fig. 4 CRISPR companies and licensing agreements. Bold lines represent non-exclusive licensing. Dashed lines represent exclusive licensing. In the middle, the four most important owners of CRISPR patents. In dark blue, companies applying CRISPR for health-related

applications. In green, companies applying CRISPR in the crop industry and biotech industry. In black, companies developing tools, cell lines and animal models

technology, with several studies pointing out unwanted cuts due to the gRNA binding elsewhere than the intended target region [27, 85]. This phenomenon is known to be accentuated in regions with sequences similar to the original sequence, e.g. paralogs genes or retrotransposons regions [24]. This feature, so far, severely hinders the technology to enter into advanced clinical phases. Screening every engineered cell for off-target effects after each genetic manipulation poses long term viability issues for the technology. Consequently, other technologies with proven track record such as TALENs are so far offering a safer solution for gene editing therapies. However, while CRISPR struggles as a standalone therapy, several efforts to minimize off-target cleavage have been reported. Recently, the development of an improved Cas9 variant with enhanced proofreading capacities has extensively reduced off-targeting effects while maintaining the high-cutting efficiency [9]. Additionally, powerful molecules with the ability to inactivate Cas proteins activity, named anti-CRISPR proteins, have been reported to significantly reduce off-targeting edits [89].

In the field of crop engineering, CRISPR techniques are currently having a major impact, facilitating cheaper, faster,

and more precise engineering in comparison to laborious and time-consuming traditional methods [3, 82]. However, it has yet to be determined whether CRISPR based gene editing of crops will be regulated the same way traditional genetically engineered crops are, which ultimately will settle its commercial value within this sector.

Currently, the industrial biotechnology field using metabolically engineered microbial cell factories is progressively shifting from studies with few genetic modifications to highly engineered strains. CRISPR has become a near-commodity in the field as a result of the available panoply of engineering tools for these microbial cell factories, as well as the complex tasks these tools can perform. While most of the CRISPR proof-of-concepts have been carried out in well characterized industrial strains, more and more complex organisms successfully generating CRISPR/Cas9 mediated genome edits are being reported. A particular example concerns secondary metabolites, which are often derived from non-model organisms, thus making the corresponding biosynthetic pathways poorly characterized especially with the host being difficult to genetically engineer with traditional tools. In this example, one could either consider using

Fig. 5 Map of key CRISPR players

CRISPR technology to integrate this large pathway into a well characterized organism, or, directly genetically engineer the host organism to further enhance the product formation or elucidate its idiosyncrasies [52, 75].

Acknowledgements The authors would like to thank Jens Christian Nielsen, Paulo Gonçalves Teixeira, and Philip Hemme for valuable feedbacks and discussions.

Funding This work was funded by the Novo Nordisk Foundation, Swedish Foundation for Strategic Research, Åforsk and the Knut and Alice Wallenberg foundation.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Bao Z, Xiao H, Liang J, Zhang L, Xiong X, Sun N, Si T, Zhao H (2014) Homology-integrated CRISPR–Cas (HI-CRISPR) system for one-step multigene disruption in *Saccharomyces cerevisiae*. *ACS Synth Biol* 4(5):585–594
- Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P (2007) CRISPR provides acquired resistance against viruses in prokaryotes. *Science* 315(5819):1709–1712
- Belhaj K, Chaparro-Garcia A, Kamoun S, Patron NJ, Nekrasov V (2015) Editing plant genomes with CRISPR/Cas9. *Curr Opin Biotechnol* 30(32):76–84
- Bikard D, Marraffini LA (2013) Control of gene expression by CRISPR-Cas systems. *F1000prime Rep* 5
- Bolotin A, Quinquis B, Sorokin A, Ehrlich SD (2005) Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. *Microbiology* 151(8):2551–2561
- Carroll D (2011) Genome engineering with zinc-finger nucleases. *Genetics* 188(4):773–782
- Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, Iyer EP, Lin S, Kiani S, Guzman CD, Wiegand DJ, Ter-Ovanesyan D (2015) Highly efficient Cas9-mediated transcriptional programming. *Nat Methods* 12(4):326–328
- Chavez A, Tuttle M, Pruitt BW, Ewen-Campen B, Chari R, Ter-Ovanesyan D, Haque SJ, Cecchi RJ, Kowal EJ, Buchthal J, Housden BE (2016) Comparison of Cas9 activators in multiple species. *Nat Methods* 13(7):563–567
- Chen JS, Dagdas YS, Kleinstiver BP, Welch MM, Harrington LB, Sternberg SH, Joung JK, Yildiz A, Doudna JA (2017) Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. *Nature* 550(7676):407
- Cho JS, Choi KR, Prabowo CP, Shin JH, Yang D, Jang J, Lee SY (2017) CRISPR/Cas9-coupled recombineering for metabolic engineering of *Corynebacterium glutamicum*. *Metab Eng* 42(2):157–167
- Cleto S, Jensen JV, Wendisch VF, Lu TK (2016) *Corynebacterium glutamicum* metabolic engineering with CRISPR interference (CRISPRi). *ACS Synth Biol* 5(5):375–385
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. *Science* 339(6121):819–823
- Cress BF, Leitz QD, Kim DC, Amore TD, Suzuki JY, Linhardt RJ, Koffas MA (2017) CRISPRi-mediated metabolic engineering

- of *E. coli* for *O*-methylated anthocyanin production. *Microb Cell Fact* 16(1):10
14. Cress BF, Toparlak OD, Guleria S, Lebovich M, Stieglitz JT, Englaender JA, Jones JA, Linhardt RJ, Koffas MA (2015) CRISPR-Brick: modular combinatorial assembly of type II-A CRISPR arrays for dCas9-mediated multiplex transcriptional repression in *E. coli*. *ACS Synth Biol* 4(9):987–1000
 15. David F, Siewers V (2015) Advances in yeast genome engineering. *FEMS Yeast Res* 15(1):1–4
 16. Deaner M, Alper HS (2017) Systematic testing of enzyme perturbation sensitivities via graded dCas9 modulation in *Saccharomyces cerevisiae*. *Metab Eng* 31(40):14–22
 17. Deaner M, Mejia J, Alper HS (2017) Enabling graded and large-scale multiplex of desired genes using a dual-mode dCas9 activator in *Saccharomyces cerevisiae*. *ACS Synth Biol* 6(10):1931–1943
 18. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol* 34(2):184–191
 19. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE (2014) Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. *Nat Biotechnol* 32(12):1262–1267
 20. Doudna JA, Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. *Science* 346.6213:1258096
 21. Egelie KJ, Graff GD, Strand SP, Johansen B (2016) The emerging patent landscape of CRISPR-Cas gene editing technology. *Nat Biotechnol* 34(10):1025–1031
 22. Farzadfard F, Perli SD, Lu TK (2013) Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. *ACS Synth Biol* 2(10):604
 23. Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE (2017) Cornerstones of CRISPR-Cas in drug discovery and therapy. *Nat Rev Drug Discov* 16(2):89–100
 24. Ferreira R, Gatto F, Nielsen J (2017) Exploiting off-targeting in guide-RNAs for CRISPR systems for simultaneous editing of multiple genes. *FEBS Lett*
 25. Ferreira R, Skrekas C, Nielsen J, David F (2017) Multiplexed CRISPR/Cas9 genome editing and gene regulation using Csy4 in *Saccharomyces cerevisiae*. *ACS Synth Biol*
 26. Fonfara I, Richter H, Bratovič M, Le Rhun A, Charpentier E (2016) The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. *Nature* 532(7600):517–521
 27. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nat Biotechnol* 31(9):822–826
 28. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. *Nat Biotechnol* 32(3):279–284
 29. Gaj T, Gersbach CA, Barbas CF (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. *Trends Biotechnol* 31(7):397–405
 30. Gander MW, Vrana JD, Voje WE, Carothers JM, Klavins E (2017) Digital logic circuits in yeast with CRISPR-dCas9 NOR gates. *Nat Commun* 8
 31. Garst AD, Bassalo MC, Pines G, Lynch SA, Halweg-Edwards AL, Liu R, Liang L, Wang Z, Zeitoun R, Alexander WG, Gill RT (2017) Genome-wide mapping of mutations at single-nucleotide resolution for protein, metabolic and genome engineering. *Nat Biotechnol* 35(1):48–55
 32. Gasiunas G, Barrangou R, Horvath P, Siksnys V (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc Natl Acad Sci* 109(39):E2579–E2586
 33. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, Qi LS (2014) Genome-scale CRISPR-mediated control of gene repression and activation. *Cell* 159(3):647–661
 34. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* 154(2):442–451
 35. Gordon GC, Korosh TC, Cameron JC, Markley AL, Begemann MB, Pfeiffer BF (2016) CRISPR interference as a titratable, trans-acting regulatory tool for metabolic engineering in the cyanobacterium *Synechococcus* sp. strain PCC 7002. *Metab Eng* 30(38):170–179
 36. Hilton IB, D'ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA (2015) Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nat Biotechnol* 33(5):510–517
 37. Hirano H, Gootenberg JS, Horii T, Abudayyeh OO, Kimura M, Hsu PD, Nakane T, Ishitani R, Hatada I, Zhang F, Nishimasu H (2016) Structure and engineering of *Francisella novicida* Cas9. *Cell* 164(5):950–961
 38. Horwitz AA, Walter JM, Schubert MG, Kung SH, Hawkins K, Platt DM, Hernday AD, Mahatdejkul-Meadows T, Szeto W, Chandran SS, Newman JD (2015) Efficient multiplexed integration of synergistic alleles and metabolic pathways in yeasts via CRISPR-Cas. *Cell Syst* 1(1):88–96
 39. Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. *Cell* 157(6):1262–1278
 40. Huang CH, Shen CR, Li H, Sung LY, Wu MY, Hu YC (2016) CRISPR interference (CRISPRi) for gene regulation and succinate production in cyanobacterium *S. elongatus* PCC 7942. *Microb Cell Fact* 15(1):196
 41. Jakociūnas T, Bonde I, Herrgård M, Harrison SJ, Kristensen M, Pedersen LE, Jensen MK, Keasling JD (2015) Multiplex metabolic pathway engineering using CRISPR/Cas9 in *Saccharomyces cerevisiae*. *Metab Eng* 31(28):213–222
 42. Jakociūnas T, Jensen MK, Keasling JD (2016) CRISPR/Cas9 advances engineering of microbial cell factories. *Metab Eng* 31(34):44–59
 43. Jakociūnas T, Jensen MK, Keasling JD (2017) System-level perturbations of cell metabolism using CRISPR/Cas9. *Curr Opin Biotechnol* 31(46):134–140
 44. Jensen ED, Ferreira R, Jakociūnas T, Arsovska D, Zhang J, Ding L, Smith JD, David F, Nielsen J, Jensen MK, Keasling JD (2017) Transcriptional reprogramming in yeast using dCas9 and combinatorial gRNA strategies. *Microb Cell Fact* 16(1):46
 45. Jessop-Fabre MM, Jakociūnas T, Stovicek V, Dai Z, Jensen MK, Keasling JD, Borodina I (2016) EasyClone-MarkerFree: a vector toolkit for marker-less integration of genes into *Saccharomyces cerevisiae* via CRISPR-Cas9. *Biotechnol J* 11(8):1110–1117
 46. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 337(6096):816–821
 47. Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. *Nat Rev Mol Cell Biol* 14(1):49–55
 48. Kaczmarzyk D, Cengic I, Yao L, Hudson EP (2017) Diversion of the long-chain acyl-ACP pool in *Synechocystis* to fatty alcohols through CRISPRi repression of the essential phosphate acyltransferase PlsX. *Metab Eng* 45:59–66

49. Ke A, Ding F, Batchelor JD, Doudna JA (2007) Structural roles of monovalent cations in the HDV ribozyme. *Structure* 15(3):281–287
50. Kearns NA, Pham H, Tabak B, Genga RM, Silverstein NJ, Garber M, Maehr R (2015) Functional annotation of native enhancers with a Cas9-histone demethylase fusion. *Nat Methods* 12(5):401–403
51. Keren L, Zackay O, Lotan-Pompan M, Barenholz U, Dekel E, Sasson V, Aidelberg G, Bren A, Zeevi D, Weinberger A, Alon U (2013) Promoters maintain their relative activity levels under different growth conditions. *Mol Syst Biol* 9(1):701
52. Kim HU, Charusanti P, Lee SY, Weber T (2016) Metabolic engineering with systems biology tools to optimize production of prokaryotic secondary metabolites. *Nat Product Rep* 33(8):933–941
53. Kim SK, Han GH, Seong W, Kim H, Kim SW, Lee DH, Lee SG (2016) CRISPR interference-guided balancing of a biosynthetic mevalonate pathway increases terpenoid production. *Metab Eng* 30(38):228–240
54. Klann TS, Black JB, Chellappan M, Safi A, Song L, Hilton IB, Crawford GE, Reddy TE, Gersbach CA (2017) CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. *Nat Biotechnol* 35(6):561–568
55. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK (2016) High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* 529(7587):490–495
56. Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales AP, Li Z, Peterson RT, Yeh JR, Aryee MJ (2015) Engineered CRISPR-Cas9 nucleases with altered PAM specificities. *Nature* 523(7561):481–485
57. Korkmaz G, Lopes R, Ugalde AP, Nevedomskaya E, Han R, Myacheva K, Zwart W, Elkon R, Agami R (2016) Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. *Nat Biotechnol* 34(2):192–198
58. Kuivanen J, Wang YM, Richard P (2016) Engineering *Aspergillus niger* for galactaric acid production: elimination of galactaric acid catabolism by using RNA sequencing and CRISPR/Cas9. *Microb Cell Fact* 15(1):210
59. Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS (2013) CRISPR interference (CRISPRi) for sequence-specific control of gene expression. *Nat Protoc* 8(11):2180–2196
60. Li H, Shen CR, Huang CH, Sung LY, Wu MY, Hu YC (2016) CRISPR-Cas9 for the genome engineering of cyanobacteria and succinate production. *Metab Eng* 30(38):293–302
61. Li R, Li R, Li X, Fu D, Zhu B, Tian H, Luo Y, Zhu H (2017) Multiplexed CRISPR/Cas9-mediated metabolic engineering of γ -aminobutyric acid levels in *Solanum lycopersicum*. *Plant Biotechnol J*. <https://doi.org/10.1111/pbi.12781>
62. Li J, Meng X, Zong Y, Chen K, Zhang H, Liu J, Li J, Gao C (2016) Gene replacements and insertions in rice by intron targeting using CRISPR–Cas9. *Nat Plants* 12(2):16139
63. Li Y, Lin Z, Huang C, Zhang Y, Wang Z, Tang YJ, Chen T, Zhao X (2015) Metabolic engineering of *Escherichia coli* using CRISPR–Cas9 mediated genome editing. *Metab Eng* 30(31):13–21
64. Liang L, Liu R, Garst AD, Lee T, Beckham GT, Gill RT (2017) CRISPR Enabled trackable genome engineering for isopropanol production in *Escherichia coli*. *Metab Eng* 31(41):1
65. Liang Z, Chen K, Li T, Zhang Y, Wang Y, Zhao Q, Liu J, Zhang H, Liu C, Ran Y, Gao C (2017) Efficient DNA-free genome editing of bread wheat using CRISPR/Cas9 ribonucleoprotein complexes. *Nat Commun* 8:14261
66. Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, Kwak S, Sung BH, Sohn JH, Walukiewicz HE, Rao CV (2016) Metabolic engineering of probiotic *Saccharomyces boulardii*. *Appl Environ Microbiol* 82(8):2280–2287
67. Liu Q, Gao R, Li J, Lin L, Zhao J, Sun W, Tian C (2017) Development of a genome-editing CRISPR/Cas9 system in thermophilic fungal *Myceliophthora* species and its application to hypercellulase production strain engineering. *Biotechnol Biofuels* 10(1):1
68. Lv L, Ren YL, Chen JC, Wu Q, Chen GQ (2015) Application of CRISPRi for prokaryotic metabolic engineering involving multiple genes, a case study: controllable P (3HB-co-4HB) biosynthesis. *Metab Eng* 31(29):160–168
69. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, Barrangou R, Brouns SJ, Charpentier E, Haft DH, Horvath P (2015) An updated evolutionary classification of CRISPR–Cas systems. *Nat Rev Microbiol* 13(11):722–736
70. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. *Science* 339(6121):823–826
71. Marraffini LA, Sontheimer EJ (2010) CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. *Nat Rev Genet* 11(3):181–190
72. Meng J, Feng R, Zheng G, Ge M, Mast Y, Wohlleben W, Gao J, Jiang W, Lu Y (2017) Improvement of pristnamycin I (PI) production in *Streptomyces pristinaespiralis* by metabolic engineering approaches. *Synth Syst Biotechnol*
73. Mullard A (2017) FDA approves first CAR T therapy. *Nat Rev Drug Discov* 16(10):669
74. Mullard A (2017) Second anticancer CAR T therapy receives FDA approval. *Nat Rev Drug Discov* 16(12):818
75. Nielsen JC, Nielsen J (2017) Development of fungal cell factories for the production of secondary metabolites: linking genomics and metabolism. *Synth Syst Biotechnol* 2:5–12. <https://doi.org/10.1016/j.synbio.2017.02.002>
76. Nissim L, Perli SD, Fridkin A, Perez-Pinera P, Lu TK (2014) Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. *Mol Cell* 54(4):698–710
77. Ozaki A, Konishi R, Otomo C, Kishida M, Takayama S, Matsumoto T, Tanaka T, Kondo A (2017) Metabolic engineering of *Schizosaccharomyces pombe* via CRISPR–Cas9 genome editing for lactic acid production from glucose and cellobiose. *Metab Eng Commun* 1(5):60–67
78. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nat Methods* 10(10):973–976
79. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* 152(5):1173–1183
80. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell* 154(6):1380–1389
81. Ren J, Zhao Y (2017) Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. *Protein Cell*. 22:1
82. Rodríguez-Leal D, Lemmon ZH, Man J, Bartlett ME, Lippman ZB (2017) Engineering quantitative trait variation for crop improvement by genome editing. *Cell* 171(2):470–480
83. Ryan OW, Skerker JM, Maurer MJ, Li X, Tsai JC, Poddar S, Lee ME, DeLoache W, Dueber JE, Arkin AP, Cate JH (2014) Selection of chromosomal DNA libraries using a multiplex CRISPR system. *Elife* 19(3):e03703
84. Sapranauskas R, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V (2011) The *Streptococcus thermophilus* CRISPR/

- Cas system provides immunity in *Escherichia coli*. Nucl Acids Res 39(21):9275–9282
85. Schaefer KA, Wu WH, Colgan DF, Tsang SH, Bassuk AG, Mahajan VB (2017) Unexpected mutations after CRISPR-Cas9 editing in vivo. Nat Methods 14(6):547–548
 86. Shen JP, Zhao D, Sasik R, Luebeck J, Birmingham A, Bojorquez-Gomez A, Licon K, Klepper K, Pekin D, Beckett AN, Sanchez KS (2017) Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. Nat Methods
 87. Sheridan C (2017) CRISPR patent estate splinters. Nat Biotechnol 35(9):808–809
 88. Shi S, Liang Y, Zhang MM, Ang EL, Zhao H (2016) A highly efficient single-step, markerless strategy for multi-copy chromosomal integration of large biochemical pathways in *Saccharomyces cerevisiae*. Metab Eng 31(33):19–27
 89. Shing J, Jiang F, Liu JJ, Bray NL, Rauch BJ, Baik SH, Nogales E, Bondy-Denomy J, Corn JE, Doudna JA (2017) Disabling Cas9 by an anti-CRISPR DNA mimic. bioRxiv 129627
 90. Siksnys V, Gasiunas G (2016) Rewiring Cas9 to target new PAM sequences. Mol Cell 61(6):793–794
 91. Smith JD, Suresh S, Schlecht U, Wu M, Wagih O, Peltz G, Davis RW, Steinmetz LM, Parts L, Onge RP (2016) Quantitative CRISPR interference screens in yeast identify chemical-genetic interactions and new rules for guide RNA design. Genome Biol 17(1):45
 92. Stella S, Alcon P, Montoya G (2017) Class 2 CRISPR-Cas RNA-guided endonucleases: Swiss Army knives of genome editing. Nat Struct Mol Biol 24(11):882
 93. Stovicek V, Borodina I, Forster J (2015) CRISPR–Cas system enables fast and simple genome editing of industrial *Saccharomyces cerevisiae* strains. Metab Eng Commun 31(2):13–22
 94. Vanegas KG, Lehka BJ, Mortensen UH (2017) SWITCH: a dynamic CRISPR tool for genome engineering and metabolic pathway control for cell factory construction in *Saccharomyces cerevisiae*. Microb Cell Fact 16(1):25
 95. Wang H, La Russa M, Qi LS (2016) CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem 2(85):227–264
 96. Wen Z, Minton NP, Zhang Y, Li Q, Liu J, Jiang Y, Yang S (2017) Enhanced solvent production by metabolic engineering of a twin-clostridial consortium. Metab Eng 31(39):38–48
 97. Westbrook AW, Moo-Young M, Chou CP (2016) Development of a CRISPR-Cas9 tool kit for comprehensive engineering of *Bacillus subtilis*. Appl Environ Microbiol 82(16):4876–4895
 98. Wolter F, Puchta H (2017) Knocking out consumer concerns and regulator's rules: efficient use of CRISPR/Cas ribonucleoprotein complexes for genome editing in cereals. Genome Biol 18(1):43
 99. Wu MY, Sung LY, Li H, Huang CH, Hu YC (2017) Combining CRISPR and CRISPRi systems for metabolic engineering of *E. coli* and 1, 4-BDO biosynthesis. ACS Synth Biol 6(12):2350–2361
 100. Zalatan JG, Lee ME, Almeida R, Gilbert LA, Whitehead EH, La Russa M, Tsai JC, Weissman JS, Dueber JE, Qi LS, Lim WA (2015) Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160(1):339–350
 101. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163(3):759–771
 102. Zhang B, Liu ZQ, Liu C, Zheng YG (2016) Application of CRISPRi in *Corynebacterium glutamicum* for shikimic acid production. Biotech Lett 38(12):2153–2161
 103. Zhu X, Zhao D, Qiu H, Fan F, Man S, Bi C, Zhang X (2017) The CRISPR/Cas9-facilitated multiplex pathway optimization (CFPO) technique and its application to improve the *Escherichia coli* xylose utilization pathway. Metab Eng 1(43):37–45